Preparation method of quinazolinone compound promoted by thiol in absence of catalyst

By promoting thiol under catalyst-free conditions, benzyl thiol and antho-aminobenzamide are dehydroaromorphized in the presence of cesium carbonate, the catalyst required for quinazolinone synthesis in the prior art is solved and The problem of harsh conditions has achieved efficient and simple preparation of quinazolinone compounds, which is suitable for the fields of biomedical and chemical engineering.

CN119019339APending Publication Date: 2024-11-26NANJING CHEM FIBER CO LTD

Patent Information

Application Number
CN202411115832.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-14
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The existing quinazolinone synthesis methods mostly require catalysts, oxidants and harsh reaction conditions, and lack simple and efficient catalyst-free methods.

Method used

Using the thiol promotion method under catalyst-free conditions, quinazolinone compounds were synthesized in dimethyl sulfoxide by dehydroaromatic reaction in the presence of cesium carbonate. The process flow is simplified by using dimethyl sulfoxide as a solvent and an oxidizing agent.

Benefits of technology

The preparation of quinazolinone compounds with high catalytic efficiency, mild conditions and simple process has been achieved, providing low-cost, easy-to-access raw materials and high conversion efficiency, which is suitable for material needs in the biomedical and chemical fields.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019339A_ABST
    Figure CN119019339A_ABST
Patent Text Reader

Abstract

The invention discloses a preparation method of a thiol-promoted quinazolinone compound without a catalyst, and belongs to the field of organic synthesis. The method comprises the following steps: uniformly mixing anthranilamide, benzyl mercaptan and cesium carbonate in dimethyl sulfoxide, carrying out dehydroaromatization at a reaction temperature of 110-130 DEG C for a certain reaction time to prepare a quinazolinone crude product, and purifying to obtain the refined quinazolinone compound. The refined quinazolinone is obtained after purification, the content of the obtained quinazolinone is about 98%, and the method has the advantages that a metal catalyst and an additional oxidizing agent are not needed, the process is simple, and the conditions are mild.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a method for preparing quinazolinone compounds promoted by mercaptan without a catalyst, and belongs to the technical field of organic synthesis. Background Art

[0002] Quinazolinone is a class of benzopyrimidone compounds with multiple biological activities. Its structural fragments are widely present in natural products and many alkaloids. Due to its simple structure and easy modification and transformation, it is also an important intermediate for the design and synthesis of new medicines and pesticides. The application, structural modification and synthesis methods of quinazolinone have always been the hot spots in synthetic chemistry and medicinal chemistry research. There are currently many methods for the synthesis of quinazolinone compounds. In terms of raw material classification, there are mainly methods such as the one-pot cyclization reaction of o-aminobenzamide or o-aminobenzonitrile with benzaldehyde, benzyl alcohol, benzyl bromide, benzylamine, toluene, bromobenzene, terminal alkynes, etc.

[0003] The numerous properties exhibited by cesium carbonate in organic synthesis are derived from the softer Lewis acidity of cesium ions. Cesium carbonate has shown very obvious superiority over other inorganic bases, such as potassium carbonate, sodium acetate, triethylamine, and potassium phosphate. Patent CN 114807987 B discloses an electrochemical method for preparing a condensed polycyclic quinazolinone derivative, which mixes a quinazolinone compound containing an olefin, sodium trifluoromethylsulfinate, nBu4NClO, a molecular sieve, and a solvent, puts two electrodes, stirs at room temperature and in an inert gas atmosphere, and continuously passes a constant current to obtain a condensed polycyclic quinazolinone derivative. The present invention does not use harsh reaction conditions such as catalysts, oxidants, and strong bases and complex synthesis steps, the operating method is simple, the reaction conditions are mild, and the raw materials are easily available, and the conversion can be efficiently achieved by simply turning on the power.

[0004] Patent CN 116804001 A discloses a quinazolinone derivative containing pyridinium salt and its preparation method and application. The method uses quinazolinone derivative containing pyridinium salt and pyridine as raw materials, dissolves them in an organic solvent, and heats the reaction until the reaction raw materials disappear as monitored by TLC to obtain the quinazolinone derivative containing pyridinium salt; this quinazolinone derivative containing pyridinium salt is a new type of compound, which has an inhibitory effect on plant pathogenic bacteria such as citrus canker and rice bacterial blight, and can be used to prepare a drug that inhibits plant pathogenic bacteria.

[0005] Patent CN 116456986 A discloses a new crystal form of a quinazolinone derivative and a preparation method thereof, which provides crystal form D, crystal form AJ, crystal form AL, crystal form AZ, crystal form AF, crystal form Z and crystal form AE of formula (1) and their preparation methods and uses. The above crystal forms have advantages in at least one of solubility, melting point, stability, dissolution, hygroscopicity, adhesion, fluidity, biological effectiveness, processing performance, purification, preparation production, safety, etc., and provide a new and better choice for the preparation of pharmaceutical preparations containing compounds of formula (1), which is of great significance for drug development. Summary of the invention

[0006] Based on the relevant technical requirements of the background technology, the present invention uses o-aminobenzamide and arylmethyl mercaptan as substrates, hoping to achieve C(sp3)-H dehydrogenation and cyclization of arylmethyl mercaptan under catalyst-free conditions to synthesize quinazolinone compounds, find a simple, effective and universal method for the synthesis of quinazolinone, and further verify the dual role of arylmethyl mercaptan as a substrate containing an inert CH bond and an organic catalyst.

[0007] The present invention aims to provide a method for preparing quinazolinone promoted by mercaptan without a catalyst, which has high catalytic efficiency, mild conditions and simple process. The prepared quinazolinone compounds meet the requirements for materials in the fields of biomedicine and chemical industry.

[0008] The present invention specifically adopts the following technical scheme: a method for preparing quinazolinone compounds promoted by mercaptan without a catalyst, wherein o-aminobenzamide, benzyl mercaptan and cesium carbonate are uniformly mixed in dimethyl sulfoxide, and a crude quinazolinone product is prepared by dehydrogenation aromatization at a reaction temperature of 110-130° C. and a certain reaction time, and a refined quinazolinone compound is obtained after purification.

[0009] As a preferred embodiment, the cesium carbonate is cesium carbonate without crystal water, and its specific chemical formula is Cs2CO3.

[0010] As a preferred embodiment, the dimethyl sulfoxide is dimethyl sulfoxide without water, and its specific chemical formula is DMSO.

[0011] As a preferred embodiment, the molar ratio of the o-aminobenzamide to the benzyl mercaptan is 1:2.

[0012] As a preferred embodiment, the molar ratio of the o-aminobenzamide to the cesium carbonate is 1:2.

[0013] As a preferred embodiment, the reaction temperature is 120°C.

[0014] As a preferred embodiment, the reaction time is 12-14 hours.

[0015] As a preferred embodiment, the purification process is as follows: after the reaction is completed, the reaction is cooled to room temperature, the insoluble impurities are removed by filtration with diatomaceous earth, and the organic phase is washed with ethyl acetate, the organic phase is dried over anhydrous Na2SO4, filtered, the solvent is removed by rotary evaporation, and the residue is separated and purified by column chromatography, ethyl acetate: petroleum ether = 1:2 to 1:6, eluted with ethyl acetate, the solvent is evaporated by rotary evaporation, and the refined quinazolinone compound product is obtained after drying.

[0016] As a preferred embodiment, the ethyl acetate and petroleum ether are both analytically pure.

[0017] As a preferred embodiment, the drying method is vacuum drying or blast drying, the drying temperature is 35 to 50° C., and the drying time is 12 to 24 hours.

[0018] The beneficial effects achieved by the present invention are as follows: (1) the present invention discloses the application of benzyl mercaptan as a substrate to catalyze the dehydrogenation aromatization of o-aminobenzamide, which provides a new choice for the synthesis of quinazolinone compounds; (2) the raw materials used in the present invention are inexpensive and easy to obtain, and the cesium carbonate without crystal water has a mild Lewis acidity and a high conversion efficiency in organic synthesis; (3) the dimethyl sulfoxide used in the present invention acts as a solvent and an oxidant at the same time, and there is no need to add an oxidant, the system is simple, impurities are easy to remove, and industrial production is easy; (4) compared with the prior art, the present invention finds after in-depth research that benzyl mercaptan can promote the synthesis of quinazolinone compounds. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 It is the hydrogen nuclear magnetic resonance spectrum of Example 1 of the present invention.

[0020] Figure 2 It is the carbon-13 nuclear magnetic resonance spectrum of Example 1 of the present invention.

[0021] Figure 3 This is the hydrogen nuclear magnetic resonance spectrum of Example 2 of the present invention.

[0022] Figure 4 It is the carbon-13 nuclear magnetic resonance spectrum of Example 2 of the present invention.

[0023] Figure 5 This is the hydrogen nuclear magnetic resonance spectrum of Example 3 of the present invention.

[0024] Figure 6 It is the carbon-13 nuclear magnetic resonance spectrum of Example 3 of the present invention.

[0025] Figure 7 It is the hydrogen nuclear magnetic resonance spectrum of Example 4 of the present invention.

[0026] Figure 8 It is the carbon-13 nuclear magnetic resonance spectrum of Example 4 of the present invention.

[0027] Fig. 9 This is the hydrogen nuclear magnetic resonance spectrum of Example 5 of the present invention.

[0028] Fig.10 It is the carbon-13 nuclear magnetic resonance spectrum of Example 5 of the present invention.

[0029] Fig.11 This is the fluorine-19 magnetic resonance imaging image of Example 5 of the present invention.

[0030] Fig.12 It is the hydrogen nuclear magnetic resonance spectrum of Example 6 of the present invention.

[0031] Fig.13 It is the carbon-13 nuclear magnetic resonance spectrum of Example 6 of the present invention.

[0032] Fig.14 This is the hydrogen nuclear magnetic resonance spectrum of Example 7 of the present invention.

[0033] Fig.15 It is the carbon-13 nuclear magnetic resonance spectrum of Example 7 of the present invention.

[0034] Fig.16 This is the hydrogen nuclear magnetic resonance spectrum of Example 8 of the present invention.

[0035] Fig.17 It is the carbon-13 nuclear magnetic resonance spectrum of Example 8 of the present invention.

[0036] Fig.18 This is the hydrogen nuclear magnetic resonance spectrum of Example 9 of the present invention.

[0037] Fig.19 It is the carbon-13 nuclear magnetic resonance spectrum of Example 9 of the present invention.

[0038] Fig. 20 This is the hydrogen nuclear magnetic resonance spectrum of Example 10 of the present invention.

[0039] Fig.21 It is the carbon-13 nuclear magnetic resonance spectrum of Example 10 of the present invention.

[0040] Fig. 22 This is the hydrogen nuclear magnetic resonance spectrum of Example 11 of the present invention.

[0041] Fig.23 It is the carbon-13 nuclear magnetic resonance spectrum of Example 11 of the present invention.

[0042] Fig.24 This is the hydrogen nuclear magnetic resonance spectrum of Example 12 of the present invention.

[0043] Fig.25 It is the carbon-13 nuclear magnetic resonance spectrum of Example 12 of the present invention. DETAILED DESCRIPTION

[0044] The present invention will be further described below in conjunction with the accompanying drawings. The following embodiments are only used to more clearly illustrate the technical solution of the present invention, and cannot be used to limit the protection scope of the present invention.

[0045] Example 1

[0046]

[0047] Take o-aminobenzamide (0.20mmol), arylmethyl mercaptan (0.40mmol), Cs2CO3 (0.40mmol, 130.3mg), DMSO (1.0mL) and a magnetic son and add them to a 10mL Schlenk reaction tube. Place the reaction tube in a preheated 120℃ parallel reactor and stir for 12 hours. After the reaction is completed, cool to room temperature, filter with diatomaceous earth to remove insoluble impurities, and rinse with ethyl acetate. The organic phase is dried over anhydrous Na2SO4, filtered, and the solvent is removed by rotary evaporation. The residue is separated and purified by column chromatography (ethyl acetate: petroleum ether = 1:2-1:6), eluted with ethyl acetate, and the solvent is evaporated by rotary evaporation. The product of quinazolinone compound is obtained by vacuum drying at 50℃ for 18h to constant weight. Yield: 98%; melting point: 236-237℃.

[0048] Product 1 H NMR and 13 The structure identified by C NMR is as follows: 1 H NMR (400MHz, DMSO-d6) δ12.56 (s, 1H), 8.20-8.15 (m, 3H), 7.86-7.82 (m, 1H), 7.75 (d, J = 7.64Hz, 1H), 7.62-7.50 (m, 4H). 13 C NMR (101 MHz, DMSO-d6) δ 162.7, 152.8, 149.2, 135.1, 133.2, 131.9, 129.1, 128.2, 128.0, 127.1, 126.3, 121.5. Figure 1 and Figure 2 shown.

[0049] Example 2

[0050]

[0051] Take 5-methyl-2-aminobenzamide (0.20mmol), arylmethyl mercaptan (0.40mmol), Cs2CO3 (0.40mmol, 130.3mg), DMSO (1.0mL) and magnetic son into a 10mL Schlenk reaction tube, place the reaction tube on a preheated 120℃ parallel reactor and stir for 12 hours. After the reaction is completed, cool to room temperature, filter with diatomaceous earth to remove insoluble impurities, and rinse with ethyl acetate. The organic phase is dried over anhydrous Na2SO4, filtered, and the solvent is removed by rotary evaporation. The residue is separated and purified by column chromatography (ethyl acetate: petroleum ether = 1:2-1:6), eluted with ethyl acetate, and the solvent is evaporated by rotary evaporation. The product of quinazolinone compound is obtained by vacuum drying at 50℃ for 18h to constant weight. Yield: 82%; melting point: 237-239℃.

[0052] Product 1 H NMR and 13 The structure identified by C NMR is as follows: 1 H NMR (400MHz, DMSO-d6) δ12.53 (s, 1H), 8.24-8.22 (dd, J = 7.68, 1.36Hz, 2H), 7.99 (d, J = 7. 52Hz,1H),7.68(d,J=6.8Hz,1H),7.61-7.51(m,3H),7.39(t,J=7.6Hz,1H),2.62(s,3H). 13 C NMR (101 MHz, DMSO-d6) δ 163.0, 151.5, 147.6, 136.1, 135.4, 133.4, 131.8, 129.1, 128.2, 126.5, 124.0, 121.3, 17.6. Figure 3 and Figure 4 shown.

[0053] Example 3

[0054]

[0055] Take 5-methoxy-2-aminobenzamide (0.20mmol), arylmethyl mercaptan (0.40mmol), Cs2CO3 (0.40mmol, 130.3mg), DMSO (1.0mL) and a magnetic son and add them to a 10mL Schlenk reaction tube. Place the reaction tube in a preheated 120℃ parallel reactor and stir for 12 hours. After the reaction is completed, cool to room temperature, filter with diatomaceous earth to remove insoluble impurities, and rinse with ethyl acetate. The organic phase is dried over anhydrous Na2SO4, filtered, and the solvent is removed by rotary evaporation. The residue is separated and purified by column chromatography (ethyl acetate: petroleum ether = 1:2-1:6), eluted with ethyl acetate, and the solvent is evaporated by rotary evaporation. The product of quinazolinone compound is obtained by vacuum drying at 50℃ for 18h to constant weight. Yield: 74%; melting point: 249-251℃.

[0056] Product 1 H NMR and 13 The structure identified by C NMR is as follows: 1 H NMR (400MHz, DMSO-d6) δ12.52(s,1H),8.34-7.99(m,2H),7.71(d,J=8.9Hz,1H),7.65-7.49(m,4H),7.45(dd,J=8.9,3.0Hz,1H),3.90(s,3H). 13 C NMR (101 MHz, DMSO-d6) δ 162.5, 158.2, 150.6, 143.7, 133.3, 131.5, 129.7, 129.1, 128.0, 124.6, 122.2, 106.3, 56.1. Figure 5 and Figure 6 shown.

[0057] Example 4

[0058]

[0059] 5-Chloro-2-aminobenzamide (0.20mmol), arylmethyl mercaptan (0.40mmol), Cs2CO3 (0.40mmol, 130.3mg), DMSO (1.0mL) and a magnetic son were added to a 10mL Schlenk reaction tube, and the reaction tube was placed on a preheated 120℃ parallel reactor and stirred for 12 hours. After the reaction was completed, it was cooled to room temperature, filtered with diatomaceous earth to remove insoluble impurities, and rinsed with ethyl acetate. The organic phase was dried over anhydrous Na2SO4, filtered, and the solvent was removed by rotary evaporation. The residue was separated and purified by column chromatography (ethyl acetate: petroleum ether = 1:2-1:6), eluted with ethyl acetate, and the solvent was evaporated by rotary evaporation. It was vacuum dried at 50℃ for 18h to constant weight to obtain the quinazolinone compound product. Yield: 72%; melting point: 212-213℃.

[0060] Product 1 H NMR and 13 The structure identified by C NMR is as follows: 1 H NMR (400MHz, DMSO-d6) δ12.72(s,1H),8.22-8.15(m,2H),8.09(d,J=2.5Hz,1H),7.87(dd,J=8.7,2.5Hz,1H),7.77(d,J=8.7Hz,1H),7.64-7.53(m,3H). 13 C NMR (101 MHz, DMSO-d6) δ 161.8, 153.4, 147.9, 135.2, 132.9, 132.1, 131.2, 130.2, 129.1, 128.3, 125.3, 122.7. Figure 7 and Figure 8 shown.

[0061] Example 5

[0062]

[0063] 5-Fluoro-2-aminobenzamide (0.20mmol), arylmethyl mercaptan (0.40mmol), Cs2CO3 (0.40mmol, 130.3mg), DMSO (1.0mL) and a magnetic son were added to a 10mL Schlenk reaction tube, and the reaction tube was placed on a preheated 120℃ parallel reactor and stirred for 12 hours. After the reaction was completed, it was cooled to room temperature, filtered with diatomaceous earth to remove insoluble impurities, and rinsed with ethyl acetate. The organic phase was dried over anhydrous Na2SO4, filtered, and the solvent was removed by rotary evaporation. The residue was separated and purified by column chromatography (ethyl acetate: petroleum ether = 1:2-1:6), eluted with ethyl acetate, and the solvent was evaporated by rotary evaporation. It was vacuum dried at 50℃ for 18h to constant weight to obtain the quinazolinone compound product. Yield: 73%; melting point: 282-284℃.

[0064] Product 1 H NMR and 13 The structure identified by C NMR is as follows: 1 H NMR (400MHz, DMSO-d6) δ12.68(s,1H),8.17(d,J=7.56Hz,2H),7.87-7.79(m,2H),7.73(td,J=8.7,3.0Hz,1H),7.64-7.52(m,3H). 13 C NMR(101MHz,DMSO-d6)δ161.9(d,J=51.0Hz),159.2,152.4,146.1,133.0,131.9,1 30.8, 129.1, 128.2, 123.6 (d, J = 51.0Hz), 122.7 (d, J = 8.3Hz), 111.0 (d, J = 23.4Hz). 19 FNMR (376MHz, DMSO-d6) δ-113.5. Fig. 9 , Fig.10 and Fig.11 shown.

[0065] Example 6

[0066]

[0067] Take 4-chloro-2-aminobenzamide (0.20mmol), arylmethyl mercaptan (0.40mmol), Cs2CO3 (0.40mmol, 130.3mg), DMSO (1.0mL) and a magnetic son and add them to a 10mL Schlenk reaction tube. Place the reaction tube in a preheated 120℃ parallel reactor and stir for 12 hours. After the reaction is completed, cool to room temperature, filter with diatomaceous earth to remove insoluble impurities, and rinse with ethyl acetate. The organic phase is dried over anhydrous Na2SO4, filtered, and the solvent is removed by rotary evaporation. The residue is separated and purified by column chromatography (ethyl acetate: petroleum ether = 1:2-1:6), eluted with ethyl acetate, and the solvent is evaporated by rotary evaporation. The product of quinazolinone compound is obtained by vacuum drying at 50℃ for 18h to constant weight. Yield: 43%; melting point: 291-292℃.

[0068] Product 1 H NMR and 13 The structure identified by C NMR is as follows: 1 H NMR (400MHz, DMSO-d6) δ12.67 (s, 1H), 8.22-8.10 (m, 3H), 7.78 (d, J = 2.0Hz, 1H), 7.64-7.51 (m, 4H). 13 C NMR (101 MHz, DMSO-d6) δ 162.2, 154.3, 150.3, 139.6, 132.8, 132.2, 129.1, 128.4, 128.4, 127.3, 127.0, 120.2. Fig.12 and Fig.13 shown.

[0069] Example 7

[0070]

[0071] Take N-methylbenzamide (0.20mmol), arylmethyl mercaptan (0.40mmol), Cs2CO3 (0.40mmol, 130.3mg), DMSO (1.0mL) and magnetic son into a 10mL Schlenk reaction tube, place the reaction tube on a preheated 120℃ parallel reactor and stir for 12 hours. After the reaction is completed, cool to room temperature, filter with diatomaceous earth to remove insoluble impurities, and rinse with ethyl acetate. The organic phase is dried over anhydrous Na2SO4, filtered, and the solvent is removed by rotary evaporation. The residue is separated and purified by column chromatography (ethyl acetate: petroleum ether = 1:2-1:6), eluted with ethyl acetate, and the solvent is evaporated by rotary evaporation. The product of quinazolinone compound is obtained by vacuum drying at 50℃ for 18h to constant weight. Yield: 90%; melting point: 101-103℃.

[0072] Product1 H NMR and 13 The structure identified by C NMR is as follows: 1 H NMR (400MHz, DMSO-d6) δ8.15 (dd, J=8.0, 1.5Hz, 1H), 7.83-7.79 (m, 1H), 7.66-7.62 (m, 3H), 7.56-7.52 (m, 4H), 3.34 (s, 3H). 13 CNMR (101MHz, DMSO-d6)δ162.1,156.6,147.5,135.9,134.8,130.3,128.9,128.7,127.6,127.3,126.6,120.6,34.4. Fig.14 and Fig.15 shown.

[0073] Example 8

[0074]

[0075] Take 2-amino-3-pyridine benzamide (0.20mmol), arylmethyl mercaptan (0.40mmol), Cs2CO3 (0.40mmol, 130.3mg), DMSO (1.0mL) and a magnetic son and add them to a 10mL Schlenk reaction tube. Place the reaction tube in a preheated 120℃ parallel reactor and stir for 12 hours. After the reaction is completed, cool to room temperature, filter with diatomaceous earth to remove insoluble impurities, and rinse with ethyl acetate. The organic phase is dried over anhydrous Na2SO4, filtered, and the solvent is removed by rotary evaporation. The residue is separated and purified by column chromatography (ethyl acetate: petroleum ether = 1:2-1:6), eluted with ethyl acetate, and the solvent is evaporated by rotary evaporation. The product of quinazolinone compound is obtained by vacuum drying at 50℃ for 18h to constant weight. Yield: 44%; melting point: 284-285℃.

[0076] Product 1 H NMR and 13 The structure identified by C NMR is as follows: 1 H NMR (400MHz, DMSO-d6) δ12.83(s,1H),8.98(dd,J=4.6,2.1Hz,1H),8.54(dd,J=7.8,2.0Hz,1H),8.23(d,J=6.9Hz,2H),7.68-7.50(m,4H). 13 C NMR (101 MHz, DMSO-d6) δ 163.1, 158.6, 156.1, 155.5, 135.5, 132.5, 131.9, 128.7, 128.1, 122.2, 116.1. Fig.16 and Fig.17 shown.

[0077] Example 9

[0078]

[0079] Take 2-aminobenzamide (0.20mmol), 2-methylbenzyl mercaptan (0.40mmol), Cs2CO3 (0.40mmol, 130.3mg), DMSO (1.0mL) and a magnetic son and add them to a 10mL Schlenk reaction tube. Place the reaction tube in a preheated 120℃ parallel reactor and stir for 12 hours. After the reaction is completed, cool to room temperature, filter with diatomaceous earth to remove insoluble impurities, and rinse with ethyl acetate. The organic phase is dried over anhydrous Na2SO4, filtered, and the solvent is removed by rotary evaporation. The residue is separated and purified by column chromatography (ethyl acetate: petroleum ether = 1:2-1:6), eluted with ethyl acetate, and the solvent is evaporated by rotary evaporation. The product of quinazolinone compound is obtained by vacuum drying at 50℃ for 18h to constant weight. Yield: 70%; melting point: 217-218℃.

[0080] Product 1 H NMR and 13 The structure identified by C NMR is as follows: 1 H NMR (400MHz, DMSO-d6) δ12.45 (s, 1H), 8.17 (d, J = 7.0Hz, 1H), 7.86-7.82 (m, 1H), 7.69 ( d,J=8.1Hz,1H),7.60-7.47(m,2H),7.46-7.42(m,1H),7.37-7.32(m,2H),2.39(s,3H). 13 C NMR (101 MHz, DMSO-d6) δ 161.8, 154.4, 148.7, 136.1, 134.5, 134.2, 130.5, 129.9, 129.1, 127.3, 126.6, 125.8, 125.7, 120.9, 19.5. Fig.18 and Fig.19 shown.

[0081] Example 10

[0082]

[0083] Take 2-aminobenzamide (0.20mmol), 2-thienyl methyl mercaptan (0.40mmol), Cs2CO3 (0.40mmol, 130.3mg), DMSO (1.0mL) and a magnetic son and add them to a 10mL Schlenk reaction tube. Place the reaction tube in a preheated 120℃ parallel reactor and stir for 12 hours. After the reaction is completed, cool to room temperature, filter with diatomaceous earth to remove insoluble impurities, and rinse with ethyl acetate. The organic phase is dried over anhydrous Na2SO4, filtered, and the solvent is removed by rotary evaporation. The residue is separated and purified by column chromatography (ethyl acetate: petroleum ether = 1:2-1:6), eluted with ethyl acetate, and the solvent is evaporated by rotary evaporation. The product of quinazolinone compound is obtained by vacuum drying at 50℃ for 18h to constant weight. Yield: 60%; melting point: 235-238℃.

[0084] Product 1 H NMR and 13 The structure identified by C NMR is as follows: 1 H NMR (400MHz, DMSO-d6) δ12.66(s,1H),8.23(dd,J=3.8,1.2Hz,1H),8.13(dd,J=7.9,1.6Hz,1H),7.87(d, J=5.0Hz,1H),7.83-7.78(m,1H),7.65(m,J=8.1Hz,1H),7.51-7.47(m,1H),7.24(dd,J=5.1,3.8Hz,1H). 13 CNMR (101MHz, DMSO-d6)δ162.4,149.0,148.4,137.8,135.2,132.7,129.9,129.0,127.3,126.8,126.5,121.3. Fig. 20 and Fig.21 shown.

[0085] Embodiment 11

[0086]

[0087] Take 2-aminobenzamide (0.20mmol), 4-chlorobenzyl mercaptan (0.40mmol), Cs2CO3 (0.40mmol, 130.3mg), DMSO (1.0mL) and a magnetic son and add them to a 10mL Schlenk reaction tube. Place the reaction tube in a preheated 120℃ parallel reactor and stir for 12 hours. After the reaction is completed, cool to room temperature, filter with diatomaceous earth to remove insoluble impurities, and rinse with ethyl acetate. The organic phase is dried over anhydrous Na2SO4, filtered, and the solvent is removed by rotary evaporation. The residue is separated and purified by column chromatography (ethyl acetate: petroleum ether = 1:2-1:6), eluted with ethyl acetate, and the solvent is evaporated by rotary evaporation. The product of quinazolinone compound is obtained by vacuum drying at 50℃ for 18h to constant weight. Yield: 29%; melting point: 171-172℃.

[0088] Product 1 H NMR and 13 The structure identified by C NMR is as follows: 1 H NMR(400MHz,DMSO-d6)δ12.62(s,1H),8.24-8.20(m,2H),8.17(dd,J=7.9,1.6Hz,1 H),7.88-7.84(m,1H),7.76(d,J=7.7Hz,1H),7.66-7.63(m,2H),7.57-7.53(m,1H). 13 C NMR (101 MHz, DMSO-d6) δ 162.2, 151.4, 148.5, 136.3, 134.6, 131.6, 129.6, 128.6, 127.4, 126.8, 125.9, 121.0. Fig. 22 and Fig.23 shown.

[0089] Example 12

[0090]

[0091] Take 2-aminobenzamide (0.20mmol), 2-furanmethylthiol (0.40mmol), Cs2CO3 (0.40mmol, 130.3mg), DMSO (1.0mL) and a magnetic son and add them to a 10mL Schlenk reaction tube. Place the reaction tube in a preheated 120℃ parallel reactor and stir for 12 hours. After the reaction is completed, cool to room temperature, filter with diatomaceous earth to remove insoluble impurities, and rinse with ethyl acetate. The organic phase is dried over anhydrous Na2SO4, filtered, and the solvent is removed by rotary evaporation. The residue is separated and purified by column chromatography (ethyl acetate: petroleum ether = 1:2-1:6), eluted with ethyl acetate, and the solvent is evaporated by rotary evaporation. The product of quinazolinone compound is obtained by vacuum drying at 50℃ for 18h to constant weight. Yield: 40%; melting point: 219-221℃.

[0092] Product 1 H NMR and 13 The structure identified by C NMR is as follows: 1 H NMR(400MHz, DMSO-d6)δ12.56(s,1H),8.17(dd,J=7.9,1.6Hz,1H),8.05(d,J=1.7Hz,1H),7.88-7.84 (m,1H),7.74(d,J=7.7Hz,1H),7.68(d,J=3.6Hz,1H),7.56-7.52(m,1H),6.80(dd,J=3.6,1.8Hz,1H). 13 C NMR (101 MHz, DMSO-d6) δ 161.5, 148.6, 146.6, 146.1, 144.0, 134.6, 127.2, 126.5, 125.9, 121.1, 114.5, 112.5. Fig.24 and Fig.25 shown.

[0093] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the above embodiments, ordinary technicians in the relevant field should understand that the specific implementation methods of the present invention can still be modified or replaced by equivalents. Any modification or equivalent replacement that does not depart from the spirit and scope of the present invention should be covered within the scope of protection of the claims of the present invention.

Claims

1. A method for preparing a quinazolinone compound promoted by mercaptan without a catalyst, characterized in that: The o-aminobenzamide, benzyl mercaptan and cesium carbonate are uniformly mixed in dimethyl sulfoxide, and the crude quinazolinone is prepared by dehydrogenation aromatization at a reaction temperature of 110-130°C and a certain reaction time, and the refined quinazolinone compound is obtained after purification.

2. The method for preparing quinazolinone compounds promoted by mercaptan without catalyst according to claim 1, characterized in that: The cesium carbonate is cesium carbonate without crystal water, and its specific chemical formula is Cs2CO3.

3. The method for preparing quinazolinone compounds promoted by mercaptan without catalyst according to claim 1, characterized in that: The dimethyl sulfoxide is dimethyl sulfoxide without water, and its specific chemical formula is DMSO.

4. The method for preparing quinazolinone compounds promoted by mercaptan without catalyst according to claim 1, characterized in that: The reaction temperature is 120°C.

5. The method for preparing quinazolinone compounds promoted by mercaptan without catalyst according to claim 1, characterized in that: The molar ratio of the o-aminobenzamide to the benzyl mercaptan is 1:

2.

6. The method for preparing quinazolinone compounds promoted by mercaptan without catalyst according to claim 1, characterized in that: The molar ratio of the anthranilamide to the cesium carbonate is 1:

2.

7. The method for preparing quinazolinone compounds promoted by mercaptan without catalyst according to claim 1, characterized in that: The reaction time is 12-14 hours.

8. The method for preparing quinazolinone compounds promoted by mercaptan without catalyst according to claim 1, characterized in that: The purification process is as follows: after the reaction is completed, the mixture is cooled to room temperature, insoluble impurities are removed by filtration with diatomaceous earth, and the mixture is rinsed with ethyl acetate. The organic phase is dried over anhydrous Na2SO4, filtered, and the solvent is removed by rotary evaporation. The residue is separated and purified by column chromatography, wherein the ratio of ethyl acetate to petroleum ether is 1:2 to 1:6, the mixture is eluted with ethyl acetate, the solvent is removed by rotary evaporation, and the refined quinazolinone compound product is obtained after drying.

9. The method for preparing quinazolinone compounds promoted by mercaptan without catalyst according to claim 8, characterized in that: The ethyl acetate and petroleum ether were of analytical grade.

10. The method for preparing quinazolinone compounds promoted by mercaptan without catalyst according to claim 8, characterized in that: The drying method is vacuum drying or blast drying, the drying temperature is 35-50° C., and the drying time is 12-24 hours.

Citation Information

Patent Citations

  • An electrochemical method for preparing fused polycyclic quinazolinone derivatives

    CN114807987B

  • New crystal form of quinazolinone derivative and preparation method thereof

    CN116456986A

  • Quinazolinone derivative containing pyridinium salt as well as preparation method and application of quinazolinone derivative

    CN116804001A

Cited By

  • Method for electrocatalytic synthesis of quinazolinone derivative

    CN119640277A